Thalidomide on the comeback trail.
Hales
B F
BF
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D004247:DNA / Q000378:metabolism; D017277:Drug Approval; D004893:Erythema Nodosum / Q000188:drug therapy; D005260:Female; D005609:Free Radicals; D008431:Maternal-Fetal Exchange; D051379:Mice; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011247:Pregnancy; D011817:Rabbits; D013045:Species Specificity; D013723:Teratogens / Q000494:pharmacology*; D013792:Thalidomide / Q000494:pharmacology* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000276:Adjuvants, Immunologic; D005609:Free Radicals; D013723:Teratogens; D013792:Thalidomide; D004247:DNA